Gram Negative Bloodstream Infections
Cross-source consensus on Gram Negative Bloodstream Infections from 1 sources and 4 claims.
1 sources · 4 claims
Risks & contraindications
Highlighted claims
- Gram negative bloodstream infections are described as a major global health burden. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
- Gram negative bloodstream infections have an average 30-day mortality of 17%. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
- Antimicrobial resistance worsens the Gram negative bloodstream infection problem. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+
- Gram negative bloodstream infections occur at about 150 cases per 100,000 people per year. — Assessing the feasibility of a platform trial for Gram negative bloodstream infections: results from the vanguard phase of BALANCE+